Argan (AGX) Cash & Equivalents (2010 - 2026)

Argan (AGX) has 17 years of Cash & Equivalents data on file, last reported at $339.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 133.7% year-over-year to $339.5 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $339.5 million (up 133.7% YoY) and the FY2026 annual result came in at $339.5 million, up 133.7% from the prior year.
• Cash & Equivalents grew to $339.5 million in Q1 2026 per AGX's latest filing, from $306.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $350.5 million in Q1 2022, with the low at $136.1 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $209.0 million, with a median of $192.3 million recorded in 2022.
• Year-over-year, Cash & Equivalents sank 68.25% in 2022 and jumped 133.7% in 2026.
• Argan's Cash & Equivalents stood at $136.1 million in 2022, then surged by 36.38% to $185.6 million in 2023, then fell by 5.51% to $175.3 million in 2024, then jumped by 74.68% to $306.3 million in 2025, then rose by 10.84% to $339.5 million in 2026.
• Business Quant data shows AGX's Cash & Equivalents at $339.5 million in Q1 2026, $306.3 million in Q4 2025, and $177.8 million in Q3 2025.